We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Will Imatinib Compromise Reproductive Capacity?
- Authors
Zamah, Alberuni M.; Mauro, Michael J.; Druker, Brian J.; Oktay, Kutluk; Egorin, Merrill J.; Cedars, Marcelle I.; Rosen, Mitchell P.
- Abstract
Imatinib mesylate is the first in a family of highly effective, minimally toxic, targeted agents used widely to treat Philadelphia-positive leukemias and selected other cancers, leading to a steady rise in the prevalence of patients using such therapy. Because failure of therapy would require conventional gonadotoxic hemotherapeutics, many female patients using imatinib may choose to preserve fertility. Herein, we provide evidence of a potential negative effect of imatinib on ovarian function by reporting the first case of a woman who showed a severely compromised ovarian response to gonadotropin stimulation while on imatinib, with a normal ovarian response after stopping this medication.
- Subjects
CANCER chemotherapy; LEUKEMIA; DRUG therapy; CRYOPRESERVATION of organs, tissues, etc.; FERTILITY; HUMAN reproductive technology; CASE studies; IMATINIB
- Publication
Oncologist, 2011, Vol 16, Issue 10, p1422
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2011-0137